HANSOH PHARMA GRANTS REGENERON AN EXCLUSIVE LICENSE RIGHTS TO ITS INVESTIGATIONAL DUAL GLP-1/GIP RECEPTOR AGONIST HS-20094
- Hansoh Pharma grants Regeneron Pharmaceuticals an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, and Macau), to its investigational dual GLP-1/GIP receptor agonist.
- Hansoh Pharma receives an upfront payment of US$80 million and is eligible to receive development, regulatory, and sales milestone payments of up to US$1.93 billion, as well as double-digit royalties on potential future product sales.
SHANGHAI, June 2, 2025 — Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK),has granted Regeneron Phammaceuticals, Inc.(Regeneron, NASDAQ: REGN) an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong and Macau) to its
investigational dual GLP1/GIP receptor agonist HS-20094. HS-20094 has successfully completed multiple Phase II trials with positive efficacy and safety data and is currently being investigated in ongoing Phase III trial in China.
Under the agreement, Hansoh Pharma will receive an upfront payment of US$80 million and be eligible to receive up to US$1.93 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as double-digit royalties on potential future product sales.
The license agreement is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in the US, and any necessary regulatory filings.
Eliza Sun, Executive Director of Board, Hansoh Pharma, said: “We are excited to enter this license agreement with Regeneron Pharmaceuticals, a company with a renowned leadership team and a well-established track record in pushing the boundaries of innovative drug development. We look forward to HS-20094 potentially reaching patients worldwide through this new partnership.”
About Hansoh Pharma
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
Statements
- This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.